-
The Japanese government officially decided: dumping one million tons of nuclear waste water into the sea, mankind may face "the disaster of extinction"!
Time of Update: 2021-04-17
On August 20, it was published in the journal "Science" that once nuclear waste water is discharged into the sea, it will cause serious pollution to the marine environment, and radioactive substances may spread to the entire Pacific Ocean or even the global marine environment.
-
J Clin Oncol: Ivosidenib is safe for the treatment of gliomas and can slow down the growth rate of tumors
Time of Update: 2021-04-17
In summary, the results of this study show that in patients with mIDH1 advanced glioma, ivosidenib 500 mg once a day has good safety, prolongs the time of disease control, and reduces the growth rate of non-enhanced tumors.
-
JAMA: The effect of celecoxib combined with FOLFOX standard adjuvant chemotherapy on the disease-free survival rate of colon cancer patients
Time of Update: 2021-04-17
Recently, researchers investigated the effect of adding celecoxib to the adjuvant chemotherapy regimen of fluorouracil, calcium leucovorin and oxaliplatin (FOLFOX) on the disease-free survival rate of patients with stage III colon cancer .
-
Clin Cancer Res: The first human phase I study evaluated the application of PI3K/mTOR inhibitor GDC-0084 in patients with glioma
Time of Update: 2021-04-17
gov/31937616/" target="_blank" rel="noopener">First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma .
gov/31937616/" target="_blank" rel="noopener">First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K / mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma in this message
-
2021 American Society for Cancer Research Annual Meeting Express: New Strategies to Improve Adoptive Cell Therapy for Solid Tumors
Time of Update: 2021-04-17
Their research shows that T cells extracted from glioblastoma patients after CAR-T treatment are more responsive to tumors, produce more interferon-gamma, and have an enhanced ability to kill tumor cells.
-
Can J Cardiol: Think twice before you act!
Time of Update: 2021-04-17
They concluded that young non-smokers should not be encouraged to smoke, e-cigarettes aimed at teenagers should be banned, and laws and regulations restricting the use of teenagers should be passed and strictly enforced.
-
Lancet Oncol: Adjuvant pembrolizumab treatment can significantly improve the long-term survival rate of advanced high-risk melanoma without distant recurrence!
Time of Update: 2021-04-17
1016/S1470-2045(21)00065-6" target="_blank" rel="noopener">Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial .
-
JCO: The impact of intensive drug intervention on the safety of new oral anticancer drugs and the prognosis reported by patients
Time of Update: 2021-04-17
The primary endpoint is the number of anticancer drug-related problems (such as side effects and unresolved medication errors) and the patient's satisfaction with oral anticancer drugs after 12 weeks of treatment.
-
Lancet Oncol: The correlation between various antihypertensive drugs and cancer risk
Time of Update: 2021-04-17
Researchers collection of data from the individual subject level qualifying test, the evaluation of the vascular angiotensin converting enzyme inhibitors (of ACEIs), angiotensin II receptor blockers (ARB), β-blockers The impact of calcium channel blockers and thiazide diuretics on cancer risk.
-
PD-L1/CTLA-4 bispecific antibody!
Time of Update: 2021-04-17
com" target="_blank">/ - Corning Jerry Biopharmaceuticals (Alphamab Oncology, hereinafter referred to as "Corning Jerry") recently announced at the American Association for Cancer Research (AACR) 2021 annual meeting that KN046 combined with nab-paclitaxel for the treatment of metastatic disease Data from a Phase 1b/2 phase clinical study ( bioon.
-
Sci Adv: The "three brothers" of Parkinson's disease, cancer, and type 2 diabetes are originally in the same line
Time of Update: 2021-04-17
Shaw's now begin to explain this critical first step Parkin activated, Shaw push the measure which might be "warning" signal is sent to the AMPK by ULK1 Parkin, let Parkin after the first wave struck to examine mitochondrial damage, and When necessary, it triggers the destruction of mitochondria that are severely damaged and unable to restore function.
-
NEJM: Levatinib-Pembrolizumab is better than sunitinib in the treatment of advanced renal cell carcinoma
Time of Update: 2021-04-17
66)The study found that for patients with advanced renal cell carcinoma, levatinib-pembrolizumab treatment has a significant advantage compared with sunitinib in improving the progression-free survival and overall survival of patients.
-
Eur Radiol: Do you know the common missed and misdiagnosed factors of pancreatic ductal adenocarcinoma?
Time of Update: 2021-04-17
For each patient, the imaging images and reports were independently reviewed by two radiologists, and the following factors that could confound the evaluation were consistently recorded: inherent tumor factors, concurrent pancreatic pathology, technical limitations, and cognitive biases.
-
Br J Cancer: 5-Aminosalicylic Acid: Candidate for Prevention of Colorectal Polyps and Colorectal Cancer
Time of Update: 2021-04-17
Screening prevention In this study, the researchers aimed to investigate the potential of 5-ASA (5-aminosalicylic acid, a drug used to treat medsci.
The researchers said that 5-ASA, which is reasonably priced and well-tolerated, is a potential drug candidate for chemoprevention, which can reduce the risk of colorectal polyps and CRC in high-risk populations.
-
JAMA Sub-Journal: Changes in the pattern of cancer occurrence and death in the United States in the next 20 years
Time of Update: 2021-04-17
It is estimated that there will be 1. 8 million cancer diagnoses and more than 600,000 cancer deaths in the United States in 2020. Malignant tumors are the main cause of death for people aged 45 to 6
-
JAMA Surg: The impact of liver transplantation vs. portal vein thrombosis after liver resection on the survival of colon cancer patients with liver metastases with high tumor burden
Time of Update: 2021-04-17
Recently, researchers compared the overall survival rate (OS) of patients with colorectal cancer with high tumor burden and LR after receiving liver transplantation or PVE.
-
ESMO Open: Health-related quality of life helps predict the short-term mortality risk of patients with ovarian cancer!
Time of Update: 2021-04-17
100081" target="_blank" rel="noopener">Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients .
-
JAMA Netw Open: Is there any abuse of opioid analgesics in patients with chronic non-cancerous pain (CNCP)?
Time of Update: 2021-04-17
The main results and measurements of the study include: high-dose opioid use (200mg/d of oral morphine); request to increase the dose of opioid; request to update the prescription in advance; tamper with opioid; transfer the drug to others; and "Disease and Related Opioid dependence as defined in the tenth revised edition of the International Statistical Classification of Health Problems.
-
Odivo (nivolumab) combined with chemotherapy and Odivo combined with ipilimumab in the treatment of patients with advanced unresectable or metastatic esophageal squamous cell carcinoma can bring significant survival benefits
Time of Update: 2021-04-17
. In addition, in the PD-L1 positive population of tumors, after blinded independent center evaluation (BICR), Odivo combined with chemotherapy also showed statistical differences and clinical results in another primary endpoint of progression-free survival (PFS).
-
RET inhibitor TPX-0046 in the treatment of tumors, phase I/II SWORD-1 phase study has obtained preliminary clinical data
Time of Update: 2021-04-17
Among the 5 patients who did not undergo RET TKI, 4 showed tumor regression rates of -42%, -37%, -23%, and -3%.
Among the 5 patients who did not undergo RET TKI, 4 showed tumor regression rates of -42%, -37%, -23%, and -3%.
